169 related articles for article (PubMed ID: 16531263)
1. Stimulation of erythropoiesis by thalidomide in multiple myeloma patients: its influence on FasL, TRAIL and their receptors on erythroblasts.
Grzasko N; Dmoszynska A; Hus M; Soroka-Wojtaszko M
Haematologica; 2006 Mar; 91(3):386-9. PubMed ID: 16531263
[TBL] [Abstract][Full Text] [Related]
2. [The expression of TRAIL, TRAIL-R (DR4, DcR1) and Fas-L in patients with ovarian cancer].
Li CM; Peng ZL; Yang KX
Sichuan Da Xue Xue Bao Yi Xue Ban; 2005 May; 36(3):341-3. PubMed ID: 15931863
[TBL] [Abstract][Full Text] [Related]
3. 1'-Acetoxychavicol acetate induces apoptosis of myeloma cells via induction of TRAIL.
Ito K; Nakazato T; Murakami A; Ohigashi H; Ikeda Y; Kizaki M
Biochem Biophys Res Commun; 2005 Dec; 338(4):1702-10. PubMed ID: 16289031
[TBL] [Abstract][Full Text] [Related]
4. Dynamic changes of apoptosis-inducing ligands and Th1/Th2 like subpopulations in Hantaan virus-induced hemorrhagic fever with renal syndrome.
Liu JM; Zhu Y; Xu ZW; Ouyang WM; Wang JP; Liu XS; Cao YX; Li Q; Fang L; Zhuang R; Yang AG; Jin BQ
Clin Immunol; 2006 Jun; 119(3):245-51. PubMed ID: 16616877
[TBL] [Abstract][Full Text] [Related]
5. Involvement of tumor necrosis factor-alpha receptor 1 and tumor necrosis factor-related apoptosis-inducing ligand-(TRAIL) receptor-2/DR-5, but not Fas, in graft injury in live-donor liver transplantation.
Tashiro H; Itamoto T; Ohdan H; Arihiro K; Tateaki Y; Nakahara H; Ochi M; Hino H; Mizunuma K; Hara H; Tokita D; Onoe T; Ishiyama K; Mitsuta H; Sugino K; Asahara T
Transpl Int; 2004 Nov; 17(10):626-33. PubMed ID: 15502938
[TBL] [Abstract][Full Text] [Related]
6. Chronic lymphocytic leukemic cells exhibit apoptotic signaling via TRAIL-R1.
MacFarlane M; Inoue S; Kohlhaas SL; Majid A; Harper N; Kennedy DB; Dyer MJ; Cohen GM
Cell Death Differ; 2005 Jul; 12(7):773-82. PubMed ID: 15861184
[TBL] [Abstract][Full Text] [Related]
7. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis.
Mori E; Thomas M; Motoki K; Kataika S
FEBS Lett; 2005 Oct; 579(24):5379-84. PubMed ID: 16199041
[TBL] [Abstract][Full Text] [Related]
8. Soluble form of TRAIL, Fas and FasL in the serum of patients with B-CLL.
Jabłońska E; Kiersnowska-Rogowska B; Rogowski F; Parfieńczyk A; Puzewska W; Bukin M
Rocz Akad Med Bialymst; 2005; 50():204-7. PubMed ID: 16358967
[TBL] [Abstract][Full Text] [Related]
9. Interferon (IFN)-gamma is a main mediator of keratinocyte (HaCaT) apoptosis and contributes to autocrine IFN-gamma and tumour necrosis factor-alpha production.
Konur A; Schulz U; Eissner G; Andreesen R; Holler E
Br J Dermatol; 2005 Jun; 152(6):1134-42. PubMed ID: 15948973
[TBL] [Abstract][Full Text] [Related]
10. Upregulation of erythroblast apoptosis by malignant plasma cells: a new pathogenetic mechanism of anemia in multiple myeloma.
Silvestris F; Cafforio P; Grinello D; Dammacco F
Rev Clin Exp Hematol; 2002; Suppl 1():39-46. PubMed ID: 12735214
[TBL] [Abstract][Full Text] [Related]
11. Relationships between tumor necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) and hematopoietic activity in healthy adults.
Choi JW
Ann Hematol; 2005 Oct; 84(11):728-33. PubMed ID: 16007425
[TBL] [Abstract][Full Text] [Related]
12. TRAIL-related death receptors in normal, Lurcher and weaver mutant mouse brain.
Bäurle J; Frischmuth S; Kranda K
Neurosci Lett; 2004 Nov; 372(1-2):46-51. PubMed ID: 15531086
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of tumor necrosis factor-related apoptosis-inducing ligand and its receptors in adjuvantly treated stage III colon cancer patients.
van Geelen CM; Westra JL; de Vries EG; Boersma-van Ek W; Zwart N; Hollema H; Boezen HM; Mulder NH; Plukker JT; de Jong S; Kleibeuker JH; Koornstra JJ
J Clin Oncol; 2006 Nov; 24(31):4998-5004. PubMed ID: 17075118
[TBL] [Abstract][Full Text] [Related]
14. TNF-related apoptosis-inducing ligand and its decoy receptor osteoprotegerin in nonischemic dilated cardiomyopathy.
Schoppet M; Ruppert V; Hofbauer LC; Henser S; Al-Fakhri N; Christ M; Pankuweit S; Maisch B
Biochem Biophys Res Commun; 2005 Dec; 338(4):1745-50. PubMed ID: 16288714
[TBL] [Abstract][Full Text] [Related]
15. Sensitivity of prostate cells to TRAIL-induced apoptosis increases with tumor progression: DR5 and caspase 8 are key players.
Hesry V; Piquet-Pellorce C; Travert M; Donaghy L; Jégou B; Patard JJ; Guillaudeux T
Prostate; 2006 Jun; 66(9):987-95. PubMed ID: 16541419
[TBL] [Abstract][Full Text] [Related]
16. A probable role for trail-induced apoptosis in the pathogenesis of marrow failure. Implications from an in vitro model and from marrow of aplastic anemia patients.
Kakagianni T; Giannakoulas NC; Thanopoulou E; Galani A; Michalopoulou S; Kouraklis-Symeonidis A; Zoumbos NC
Leuk Res; 2006 Jun; 30(6):713-21. PubMed ID: 16310248
[TBL] [Abstract][Full Text] [Related]
17. Negative regulation of erythroblast maturation by Fas-L(+)/TRAIL(+) highly malignant plasma cells: a major pathogenetic mechanism of anemia in multiple myeloma.
Silvestris F; Cafforio P; Tucci M; Dammacco F
Blood; 2002 Feb; 99(4):1305-13. PubMed ID: 11830480
[TBL] [Abstract][Full Text] [Related]
18. Cardiac glycosides initiate Apo2L/TRAIL-induced apoptosis in non-small cell lung cancer cells by up-regulation of death receptors 4 and 5.
Frese S; Frese-Schaper M; Andres AC; Miescher D; Zumkehr B; Schmid RA
Cancer Res; 2006 Jun; 66(11):5867-74. PubMed ID: 16740726
[TBL] [Abstract][Full Text] [Related]
19. COX-2 inhibitors sensitize human hepatocellular carcinoma cells to TRAIL-induced apoptosis.
Yamanaka Y; Shiraki K; Inoue T; Miyashita K; Fuke H; Yamaguchi Y; Yamamoto N; Ito K; Sugimoto K; Nakano T
Int J Mol Med; 2006 Jul; 18(1):41-7. PubMed ID: 16786154
[TBL] [Abstract][Full Text] [Related]
20. Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humans.
Ishiyama K; Ohdan H; Ohira M; Mitsuta H; Arihiro K; Asahara T
Hepatology; 2006 Feb; 43(2):362-72. PubMed ID: 16440347
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
